Michael O. Braun

Partner

New York, (212) 468-8119

Download vCard

Education

Columbia University (B.A., 1970)
;
Columbia Law School (J.D., 1973)

Practices

Corporate

Life Sciences

Mergers + Acquisitions

Bar Admissions

New York

Michael Braun is head of the New York office's Corporate Group and acts as office co-chair of the Japan Practice Group. Mr. Braun is a transactional attorney whose practice focuses on U.S.-based transactional and advisory work, mostly on behalf of Asian and European companies, including many Japanese companies.

Mr. Braun represents some of Japan's largest companies in their U.S. transactions, including mergers & acquisitions, joint ventures,collaboration and other strategic alliences and corporate investments. He also works with other foreign-based and U.S. companies interested in securing strategic investments and alliances around the world. Mr. Braun's clients include global aerospace, retail, real estate, printing, food and beverages, and pharmaceutical/biotechnology businesses.

In the last five years, Mr. Braun assisted numerous Japanese companies in the pharmaceutical, life science and technology sectors in connection with their acquisitions in the U.S. of both private and public companies. He also has counseled them regarding numerous venture capital and private investments in emerging companies, focusing on drug delivery, medical devices, and medical diagnostic products as well as new pharmaceutical products.

Mr. Braun is named “Dealmaker of the Week, May 20, 2010” in connection with representing Astellas Pharma in the tender offer for OSI. , the first successful unsolicited tender offer by a Japanese company for a U.S. company. Legal 500 2011 cites a client saying Mr. Braun is “one of the best business lawyers we have worked with. He really knows our company, what is important to us and is a passionate advocate.”

Mr. Braun was born and raised in Tokyo, Japan and speaks fluent Japanese.

Astellas Pharma's Acquisition of OSI Pharmaceuticals

Represented Astellas Pharma Inc., Japan's second largest pharmaceutical company, in its $4 billion acquisition of OSI Pharmaceuticals (NASDAQ: OSIP), the first successful unsolicited tender offer by a Japanese company in the U.S.

Rohm’s acquisition of Kionix

Represented Rohm Co., Ltd., a Japanese maker of electronic and semi-conductor products in the acquisition of Kionix, Inc., a privately held company and one of the world’s leading suppliers of MEMS inertial sensors for over $233 million.

Astellas Pharma’s joint venture with Maxygen to form Perseid Therapeutics

Represented Astellas Pharma in the formation of a joint venture, Perseid Therapeutics, with Maxygen, Inc. (NASDAQ: MAXY) that will assume all of the discovery, research and development of Maxygen’s existing protein therapeutics.

Astellas Pharma’s unsolicited proposal to acquire CV Therapeutics

Represented Astellas Pharma in its offer to purchase all of the stock of CV Therapeutics (NASDAQ: CVTX) for over $1 billion.

Astellas Pharma’s acquisition of Agensys

Represented Astellas Pharma in its acquisition of Agensys, Inc., an oncology focused biotechnology company, for $537 million (cash $387 million, milestones $150 million).

Astellas Pharma’s acquisition of a North Carolina research facility

Represented Astellas Pharma U.S., Inc., Astellas Pharma’s US subsidiary, in the acquisition of Dynogen Pharmaceuticals, Inc.’s North Carolina research facility specializing in genitourinary disorders.

Dai Nippon Printing’s acquisition of Sony Chemical’s thermal ribbon business

Represented Dai Nippon Printing Co., Ltd., in the acquisition of Sony Chemicals & Information Services Corporation’s global assets constituting the thermal ribbon business.

Astellas Pharma’s $20 million Series D financing of Comentis

Represented Astellas Pharma in the purchase of Comentis Inc.’s Series D Preferred Stock for $20 million in connection with a Collaboration Agreement with Comentis with a reported value of $780 million.

Hantro Products Oy’s exchange offer with O2 Technologies

Represented Hantro Products Oy, a Finnish company in connection with an exchange offer valued at about $60 million with ON2 Technologies (AMEX: ONT), a leader in video compression software and solutions resulting in Hantro owing 12% of On2 Technologies.

Dai Nippon Printing’s acquisition of Pixel Magic Imaging

Represented Dai Nippon Printing in the initial purchase of a majority interest, and subsequent purchase pursuant to a consent solicitation of the balance of the stock of Pixel Magic Imaging, a leader in digital imaging solutions and photo kiosks.

Astellas’ acquisition of AMEVIVE® from Biogen Idec

Represented Astellas US LLC in the acquisition of the worldwide rights to AMEVIVE® from Biogen Idec Inc. (NASDAQ: BIIB).

Daiwa America’s stake purchase in Sagent Advisors

Represented Daiwa America Corporation in a business alliance agreement with, and its $52 million purchase of common stock of Sagent Advisors, Inc., a private M&A investment banking boutique firm.

Merger of Daiichi Pharmaceutical Co. and Sankyo Pharmaceutical

Represented Daiichi Pharmaceutical Co., Ltd. and Sankyo Pharmaceutical Co., Ltd. in connection with their merger creating Daiichi-Sankyo Pharmaceutical Co., Ltd.

$7.6 billion merger of Fujisawa Pharmaceutical and Yamanouchi Pharmaceutical to form Astellas Pharma Inc.

Represented Fujisawa Pharmaceutical Co., Ltd. And Yamanouchi Pharmaceutical Co., Ltd. With respect to U.S. and international issues in connection with their $7.6 billion merger creating Astellas Pharma Inc. and the Astellas group of companies.

Dai Nippon Printing’s numerous investments

Represented Dai Nippon Printing Co., Ltd.’s investments in Palo Alto Research Center; Panacea Pharma; Cangen Biotechnologies; Acucela Inc. and Molecular Imprints.